Lutenizing Hormone – Releasing Hormone (LHRHa)

INAD#
8061

Luteinizing Hormone - Releasing Hormone analogue (LHRHa) is a solution that is applied as either an intraperitoneal (IP) or intramuscular (IM) injection. LHRHa is only available for purchase through Syndel USA. The use of hormones to induce spawning in fish is critical to the success of many aquatic programs that needs hormone treatment to complete final gamete maturation to ensure spawning. The primary goal of field studies conducted under INAD #8061 is to generate data to help determine appropriate LHRHa treatment regimens for inducing gamete maturation in a variety of cultured and wildstock finfish species. Fish may be treated at a dose range of 5 to 120 microgram (µg) LHRHa per kilogram (kg) body weight with single or multiple IP or IM injections. Multiple injections will generally consist of a single “priming dose,” followed by a single “resolving dose.” Fish may be immediately released for human food use. Note: if SYNCAINE or Aqui-S® 20E is used at time of injection, then the withdrawal time for the anesthetic must be followed. To participate in the INAD Program for LHRHa visit the  data collecting site.

Please read the Study Protocol prior to any treatments.  It contains the protocol, SDS, and a copy of the forms to be used as a guide for collecting data that will be entered into the online INAD database. The FDA authorization letter(s) for this INAD is currently only available by emailing Bonnie Johnson.

Objective/Purpose
Collect supportive and pivotal data needed to establish the effectiveness of LHRHa to induce gamete maturation in a variety of fish species. LHRHa can be used to produce caviar in fish. Note: the use of sedative drugs is not allowed when collecting caviar for human consumption.
Drug Name
Luteinizing-Hormone-Releasing Hormone analogue – LHRHa

Drug Source

Syndel USA
1441 W Smith Rd
Ferndale, WA 98248
United States

Jason Montgomery
Phone
800-283-5292; Fax 360-384-0270
Target Pathogens
Not Applicable
Method of Administration
IM or IP injection only, implants not permitted
Treatment Dosage

5 - 120 microgram (μg) LHRHa per kilogram (kg) body weight

Treatment Regimen

Single or multiple treatment. Multiple treatment will generally consist of a single "priming dose," followed by a single "resolving dose." Administered IP or IM.

Investigational Withdrawal Period
  • No investigational withdrawal period is required for treated fish.
  • Note: if SYNCAINE or Aqui-S 20E is used at time of injection, then the withdrawal time for the anesthetic must be followed.
Concomitant Treatments
Only SYNCAINE or Aqui-S® 20E can be used during the LHRHa treatments. No other chemicals are allowed to be administered for 2 weeks prior; during; or 2 weeks after the LHRHa treatment. Contact AADAP for additional information regarding concomitant treatments.
Required Test Parameters
  • Investigator must collect data reporting percent ovulation and/or percent spermiation in treated fish. Investigator should also report general fish behavior and any adverse effects relating to treatment.
Limitations or Restrictions on Use of Drug
  • Investigator must follow all instructions in the Study Protocol for INAD 8061 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements.
  • Use of LHRHa implants is not authorized
  • Drug discharge must be in compliance with localNPDES permitting requirements.
Required Fee
$700/facility/year
AADAP Contact Information